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In a Phase  1 trial,  we  evaluated  the  safety  of  AERAS-402,  an  adenovirus  35-vectored  TB  vaccine  candidate
expressing  3 Mycobacterium  tuberculosis  (Mtb)  immunodominant  antigens,  in  subjects  with  and  with-
out  latent  Mtb infection.  HIV-negative,  BCG-vaccinated  Kenyan  adults  without  evidence  of  tuberculosis,
10  QuantiFERON®-TB  Gold  In-Tube  test  (QFT-G)(−)  and  10 QFT-G(+),  were  randomized  4:1  to  receive
AERAS-402  or placebo  as  two  doses,  on  Days  0 and  56,  with  follow  up  to  Day  182. There  were  no  deaths,
serious  adverse  events  or withdrawals.  For  1  AERAS-402  QFT-G(−)  and 1  AERAS-402  QFT-G(+)  subject,
there  were  3 self-limiting  severe  AEs  of  injection  site pain:  1 after  the  ﬁrst  vaccination  and  1 after  each
vaccination,  respectively.  Two  additional  severe  AEs  considered  vaccine-related  were  reported  after  the
ﬁrst vaccination  in  AERAS-402  QFT-G(+)  subjects:  elevated  blood  creatine  phosphokinase  and  neutrope-
nia,  the  latter  slowly  improving  but  remaining  abnormal  until  study  end.  AERAS-402  was  not  detected  in
urine  or  throat  cultures  for  any  subject.  In intracellular  cytokine  staining  studies,  curtailed  by  technical
issues,  we  saw  modest  CD4+  and  CD8+  T cell  responses  to Mtb  Ag85A/b  peptide  pools  among  both  QFT-
G(−)  and  (+)  subjects,  with  trends  in  the CD4+  T cells  suggestive  of boosting  after  the  second  vaccine  dose,
slightly  more  so  in QFT-G(+)  subjects.  CD4+  and  CD8+  responses  to  Mtb antigen  TB10.4  were  minimal.
Increases  in  Adenovirus  35  neu
402  recipients,  were  mostly  mi
for  AERAS-402,  in line with  oth
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Table  1
Baseline characteristics.
Placebo (N = 4) AERAS-402 (3 × 1010 vp)
QFT-G(−) (N = 8) QFT-G(+) (N = 8)
Age, mean (SD) in years 34.5 (5.3) 33.6 (9.3) 35.6 (7.0)
Male  gender, n (%) 3 (75.0) 4 (50.0) 7 (87.5)
Black,  n (%) 4 (100.0) 8 (100.0) 8 (100.0)
Quantiﬁable Ad35 neutralizing
antibody titer (titer ≥ 16)
1 (25.0) 2 (25.0) 3 (37.5)
PPD  skin test
Mean (SD) 8.3 (3.86) 9.9 (4.26) 10.3 (1.75)
Measurement
0  mm,  n (%) 0 (0.0) 1 (12.5) 0 (0.0)
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11–15  mm,  n (%) 2 (50.0) 
. Introduction
Tuberculosis (TB) remains a major global health challenge, with
n estimated 9 million cases and 1.5 million deaths in 2013 [1]. The
nly available TB vaccine, bacillus Calmette-Guérin (BCG), routinely
iven to newborns in many countries and effective in reducing
evere childhood disseminated TB [2], is inadequate for controlling
ndemic TB which is largely transmitted by adults with pulmonary
isease. Strategies to increase TB protection include new vaccines
or primary immunization as well as prime-boost combinations in
ll age groups.
AERAS-402 is a replication deﬁcient serotype 35 adenovirus
Ad35) containing DNA coding for a fusion protein created from
he sequences of 3 Mycobacterium tuberculosis (Mtb) immunodomi-
ant antigens (Ag): Ag85A, Ag85B, and TB10.4. AERAS-402 provides
rotection against Mtb challenge in a mouse model [3]. In clini-
al trials, the safety and immunogenicity of AERAS-402 have been
emonstrated in BCG-vaccinated and BCG-naïve populations in the
S and TB endemic regions of Africa [4–8].
AERAS-402 would be indicated with a prime-boost strategy
n BCG-vaccinated individuals, however, screening for latent Mtb
nfection in TB endemic regions is costly. This Phase 1 study inves-
igated the safety and immunogenicity of AERAS-402 in healthy
CG-vaccinated adults, half of whom were latently infected with
tb  as determined by the QuantiFERON-TB Gold In-Tube test (QFT-
) and half of whom were QFT-G(−).
. Materials and methods
The study was approved by the Institutional Review Board of
alter Reed Army Institute of Research, Silver Spring, MD and the
enya Medical Research Institute, Nairobi, Kenya. Participants gave
nformed consent prior to screening. The study was  conducted at
he United States Army Medical Research Unit-Kenya, Kombewa
ield Station, in accordance with the Helsinki Declaration.
This was a Phase I, randomized, placebo-controlled, double-
lind study in HIV-negative, BCG-vaccinated, healthy adults with
o evidence of TB (Table 1). Subjects were required to have had
CG vaccine more than 5 years ago, documented by either visual-
zing the scar or by medical history. Ten subjects were QFT-G(−)
nd 10 were QFT-G(+) at screening. Within each QFT-G group,
ubjects were randomized in a 4:1 ratio to receive intramuscu-
ar deltoid injections of 1 mL  AERAS-402 3 × 1010 viral particles
vp; lot number 1250.06; manufactured by Crucell Holland B.V.,
he Netherlands; stored at ≤−20 ◦C) or placebo (vaccine buffer) on
ays 0 and 56. Results for placebo subjects were pooled across QFT
trata.
Subjects were monitored for solicited and unsolicited adverse
vents (AEs) for 28 days after each vaccination, including rou-
ine biochemistry, hematology and urinalysis testing, and serious0 (0.0) 0 (0.0)
2 (25.0) 6 (75.0)
5 (62.5) 2 (25.0)
adverse events through Day 182. AEs were assessed for causality
and severity using predeﬁned criteria. Solicited AEs and temper-
ature were recorded by subjects in diary cards through 14 days
after each vaccination. Urine and throat viral cultures for detection
of AERAS-402 were collected at 2, 7, 14, and 28 days after each
vaccination.
Serum for assessment of Ad35 neutralizing antibody activity
was collected on Days 0 and 182. Antibody titers were determined
as described by Sprangers (2003), then validated at Crucell Corpo-
ration, The Netherlands [9]. Values <16 were non-quantiﬁable.
Tuberculin puriﬁed protein derivative (PPD) skin tests, mea-
sured in millimeters at the transverse induration, were performed
at screening and Day 182. Mean induration of PPD reactions was
compared between screening and Day 182 using a Wilcoxon rank
sum test.
Immunogenicity was  assessed with peripheral blood mono-
nuclear cells (PBMC) by intracellular cytokine staining (ICS). Blood
was obtained prior to each vaccination, at 7, 14, and 28 days after
each vaccination, and on Day 182, and processed as described [10].
The primary variables for assessment were the percentage of CD4+
and CD8+ T cells that produced any of 3 cytokines (IFN-, TNF-
, IL-2) following stimulation with mycobacterial peptide pools
containing the entire amino acid sequence of Ag85A and parts of
Ag85B (Ag85A/b), and the complete pool of TB10.4. Response was
measured by ﬂow cytometry with all 3 cytokines measured in a
single ﬂow cytometric channel. Median DMSO-subtracted cytokine
responses were used to summarize percentage CD4+ and CD8+ T
cell response within antigen (Ag85A/b and TB10.4) by treatment
group and, for the AERAS-402 group, QFT-G status at screening.
Samples with ≥70% cell viability and ≥0.45 × 106 cells/mL were
assayed.
3. Results
A total of 20 of 367 subjects screened were randomized between
September and December 2008 (Fig. 1). The last subject completed
the study in June 2009. Exclusion was due largely to HIV(+) sta-
tus, laboratory abnormalities or PPD skin test reactions >15 mm in
diameter (Fig. 1). Demographic and other baseline characteristics
were generally similar among the placebo, AERAS-402 QFT-G(−),
and AERAS-402 QFT-G(+) groups (Table 1). All volunteers were
black and of Kenyan descent, with a mean age of 34.6 years. All
volunteers received both vaccinations and completed the study.
There were no deaths, serious AEs, or discontinuations due to
AEs. AERAS-402 was not detected in urine or throat cultures for
any subject. All subjects reported at least 1 AE (Table 2). A few
AEs (upper respiratory tract infection, arthralgia, myalgia, blood
bilirubin increased, and decreased heart rate; all mild or moderate)
were reported more frequently in the QFT-G(+) group compared
with QFT-G(−) or placebo. Within each of the AERAS-402 groups,
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Screened for eligibilit y (n=367 ) 
Excluded (n=347) 
Most common reasons for exclusion: 
♦ HIV(+ ) sta tus 
♦ Laboratory abnormality 
♦ PPD TST reaction >15 mm 
Analy sed (n= 10)  
♦ Ex cluded fro m an alysis (n= 0)
Complete d study (n=10)  
♦ Ea rly  discontin uatio n (n=0 )
QFT-G(- ) 
Allocated to inte rven tio n 
(n= 8 AERAS- 402; n=2 placebo)  
♦ Received allocated intervention 
at  Day 0 an d Day 56 (n=10)
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♦ Early  disc onti nuati on (n=0)
QFT- G(+)  
Allocated to inte rvention 
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♦ Received al located int erven tion 
at Day 0 and  Day  56 (n=10)
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he incidence of each AE after the second vaccination was either
imilar to or lower than the incidence after the ﬁrst vaccination.
Most solicited and unsolicited AEs were mild or moderate. Two
ubjects (1 AERAS-402 QFT-G(−), 1 AERAS-402 QFT-G(+)), had self-
imiting severe solicited AEs of injection site pain, 1 after the
rst vaccination and 1 after each vaccination. Two subjects in the
ERAS-402 QFT-G(+) group had 3 severe unsolicited AEs after the
rst vaccination, 2 considered related to study vaccine (blood cre-
tine phosphokinase increased and decreased neutrophil count),
nd 1 (urine protein) considered unrelated to study vaccine. The
eutropenic subject was a 29 year old man, randomized with a
ow but normal neutrophil count of 1.61 × 103L−1 (local labo-
atory normal range: 1.5–6.6 × 103L−1) at Day 0, that became
everely low (0.98 × 103L−1) at Day 7. The neutrophil count con-
inued to decrease through Day 63 (0.86 × 103L−1), then rose to
.2 × 103L−1 (moderate in severity) at the ﬁnal evaluation on
ay 84. The subject did not develop infection of any kind during
he trial.
Quantiﬁable (titer ≥ 16) Ad35 neutralizing antibody titers at Day
 were seen in 6 (30%) subjects (1 placebo, 2 AERAS-402 QFT-G[−],
 AERAS-402 QFT-G[+]), although titers for 4 of these subjects were
ow (≤51; Fig. 2A). Among AERAS-402 vaccinated subjects, 8 (3 QFT-
[−], 5 QFT-G[+]) showed a post-vaccination increase in titer at the
nd of the study. However, for 7 of these 8 subjects the increases
ere small (maximum Day 182 titer was 137).ram of study.
A PPD reaction (1–14 mm diameter induration) occurred at
screening in all but 1 subject in the AERAS-402 QFT-G(−) group (the
PPD reaction at Day 182 was  10 mm for this subject). The AERAS-
402 QFT-G(+) group showed a statistically signiﬁcant increase in
mean induration from screening to Day 182 (10.3 to 18.5 mm;
p = 0.013), versus the AERAS-402 QFT-G(−) group for which the
increase was  not statistically signiﬁcant (9.9 mm to 11.5 mm;
p > 0.05; Fig. 2B). Mean induration in the placebo group decreased
from 8.3 mm at screening to 6.8 mm at Day 182.
ICS assays were curtailed by technical considerations. Samples
for 16% of the 180 time points (9 time points × 20 subjects) were
contaminated with Aeromonas veronii and were not assayed. Sam-
ples for a further 8% of the time points could not be assayed due to
poor viability and low cell numbers. For samples meeting quality
criteria and tested, CD8+ and CD4+ responses were seen to Ag85A/b
peptide pools in each of the AERAS-402 QFT-G(−) and AERAS-402
QFT-G(+) groups, with trends suggestive of boosting after the sec-
ond vaccine dose, especially for CD4+ T cells in QFT-G(+) subjects
(Fig. 3A and C). There was no apparent difference in CD4+ and
CD8+ T responses among QFT-G(−) and QFT-G(+) subjects. CD4+
and CD8+ responses to Mtb antigen TB10.4 were minimal, similar
to placebo values (Fig. 3B and D).Conversion of QFT-G status from screening to Day 182 was
observed for 4 subjects, 2 in each of the AERAS-402 QFT-G(−) and
AERAS-402 QFT-G(+) groups.
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Table 2
Adverse events in >1 subject overall.
Preferred term Placebo (N = 4) AERAS-402 (3 × 1010 vp)
QFT-G(−) (N = 8) QFT-G(+) (N = 8)
n  (%) n (%) n (%)
Dose 1 Dose 2 Total Dose 1 Dose 2 Total Dose 1 Dose 2 Total
Subjects with ≥1 AE 4 (100.0) 4 (100.0) 4 (100.0) 8 (100.0) 8 (100.0) 8 (100.0) 8 (100.0) 8 (100.0) 8 (100.0)
Solicited AEs
Injection site pain 1 (25.0) 3 (75.0) 3 (75.0) 6 (75.0) 6 (75.0) 8 (100.0) 7 (87.5) 7 (87.5) 7 (87.5)
URI  1 (25.0) 1 (25.0) 2 (50.0) 3 (37.5) 3 (37.5) 4 (50.0) 5 (62.5) 5 (62.5) 7 (87.5)
Headache  1 (25.0) 2 (50.0) 2 (50.0) 4 (50.0) 5 (62.5) 5 (62.5) 5 (62.5) 3 (37.5) 6 (75.0)
Arthralgia  – 2 (50.0) 2 (50.0) 2 (25.0) 1 (12.5) 2 (25.0) 3 (37.5) 4 (50.0) 5 (62.5)
Myalgia  – 1 (25.0) 1 (25.0) 2 (25.0) 2 (25.0) 2 (25.0) 5 (62.5) 2 (25.0) 5 (62.5)
Fatigue  1 (25.0) 2 (50.0) 2 (50.0) 4 (50.0) 2 (25.0) 4 (50.0) 3 (37.5) 3 (37.5) 3 (37.5)
Oropharyngeal pain 1 (25.0) 1 (25.0) 2 (50.0) 2 (25.0) 2 (25.0) 3 (37.5) 3 (37.5) 0 (0.0) 3 (37.5)
Conjunctivitis – 1 (25.0) 1 (25.0) 2 (25.0) 2 (25.0) 2 (25.0) 2 (25.0) 1 (12.5) 3 (37.5)
Dysuria  – – – – – – 1 (12.5) 1 (12.5) 2 (25.0)
Injection  site swelling – – – – – – 1 (12.5) 1 (12.5) 2 (25.0)
Malaise  – – – – – – 2 (25.0) 1 (12.5) 2 (25.0)
Diarrhea  – – – 1 (12.5) 1 (12.5) 2 (25.0) 1 (12.5) – 1 (12.5)
Unsolicited AEs
Neutrophil count decreased 2 (50.0) – 2 (50.0) 3 (37.5) 3 (37.5) 4 (50.0) 4 (50.0) 3 (37.5) 6 (75.0)
PT  prolonged – 3 (75.0) 3 (75.0) 1 (12.5) 1 (12.5) 2 (25.0) 2 (25.0) 2 (25.0) 4 (50.0)
Blood  bilirubin increased 1 (25.0) 1 (25.0) 1 (25.0) 1 (12.5) – 1 (12.5) 4 (50.0) 1 (12.5) 4 (50.0)
Heart  rate decreased 1 (25.0) – 1 (25.0) 1 (12.5) – 1 (12.5) 4 (50.0) 1 (12.5) 4 (50.0)
Blood  CPK increased 1 (25.0) 2 (50.0) 2 (50.0) 1 (12.5) – 1 (12.5) 2 (25.0) 1 (12.5) 3 (37.5)
Malaria  1 (25.0) – 1 (25.0) 1 (12.5) – 1 (12.5) 2 (25.0) 1 (12.5) 3 (37.5)
Lymphadenopathy – 1 (25.0) 1 (25.0) – – – 2 (25.0) 1 (12.5) 2 (25.0)
Abdominal pain – – – – – – 2 (25.0) – 2 (25.0)
Gastroenteritis – – – – – – – 2 (25.0) 2 (25.0)
Activated  PTT prolonged – 1 (25.0) 1 (25.0) 2 (25.0) – 2 (25.0) – 1 (12.5) 1 (12.5)
Abdominal discomfort – 1 (25.0) 1 (25.0) 1 (12.5) – 1 (12.5) – 1 (12.5) 1 (12.5)
Urinary  tract infection – 1 (25.0) 1 (25.0) – 1 (12.5) 1 (12.5) – 1 (12.5) 1 (12.5)
Protein  urine – 1 (25.0) 1 (25.0) 1 (12.5) – 1 (12.5) 1 (12.5) – 1 (12.5)
Back  pain – – – – 1 (12.5) 1 (12.5) – 1 (12.5) 1 (12.5)
Gastritis  – – – – 1 (12.5) 1 (12.5) 1 (12.5) – 1 (12.5)
Nasopharyngitis – – – 1 (12.5) – 1 (12.5) – 1 (12.5) 1 (12.5)
ALT  increased – – – – 1 (12.5) 1 (12.5) 1 (12.5) – 1 (12.5)
Eosinophil  count increased – – – – 1 (12.5) 1 (12.5) 1 (12.5) – 1 (12.5)
Lymphocytes decreased – – – – 1 (12.5) 1 (12.5) 1 (12.5) – 1 (12.5)
Nausea  – – – 1 (12.5) 1 (12.5) 2 (25.0) – – –
Red  blood cells urine – 1 (25.0) 1 (25.0) – 1 (12.5) 1 (12.5) – – –
Trichomoniasis – 1 (25.0) 1 (25.0) – 1 (12.5) 1 (12.5) – – –
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Fig. 2. Adenovirus 35 Neutralizing Antibody and PPD Results. QFT-G status reﬂects
screening values. (A) Adenovirus 35 neutralizing antibody titers on Days 0 and 182;
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<16) were set to 8. (B) Mean induration of PPD skin test reactions at screening and
ay 182. p-values determined by Wilcoxon rank sum test.
. Discussion
This small study was speciﬁcally designed to compare AERAS-
02 in QFT-G(+) and QFT-G(−) subjects in a region endemic for
B, with stratiﬁcation by baseline QFT-G status. Although QFT-G(+)
tatus may  be indicative of latent TB infection, none of the QFT-
(+) subjects who received either AERAS-402 or placebo developed
B disease during this 6-month study. There were no deaths or
erious AEs, and AERAS-402 was found acceptably safe and toler-
ble in 16 BCG-vaccinated Kenyan adults, 8 each of whom were
FT-G(−) and, for the ﬁrst time in a trial of AERAS-402, QFT-G(+)
re-immunization.
We found an increased incidence of some mild or moderate
Es in QFT-G(+) subjects, but the AE proﬁles in the QFT-G(−)
nd QFT-G(+) AERAS-402 groups were otherwise consistent with
hat seen previously in BCG-vaccinated QFT-G(−) South African
dults [4]. Most of our subjects developed injection site pain, with
hree incidences graded as severe in one QFT-G(−) and one QFT-
(+) subject. One 29 year old male subject, who  had a low but
ithin normal range neutrophil count of 1.61 × 103L−1 on Day
, developed severe neutropenia during the study (lowest value,
.86 × 103L−1). By the ﬁnal evaluation on Day 84, the neutrophil
ount had risen to 1.2 × 103L−1 (moderate in severity). The sub-
ect did not develop an infection of any kind during the study.
ypically, an adult with <500 neutrophils/L raises risk for infec-
ion. The reason for the neutropenia after immunization remained
nknown.4 (2016) 2430–2436
Due to the poor quality of many immunology cell samples (i.e.,
contamination, poor viability, low cell numbers), as well as the
small number of subjects, our ICS results should be interpreted with
caution. Nonetheless, other studies show that AERAS-402 induces
poly-functional CD4+ and CD8+ T cells in BCG-vaccinated healthy
and HIV-infected adults in South Africa [4,6], as well as healthy
adults in the US primed with BCG 3 or 6 months before AERAS-402
boosting [5]. The CD4+ and CD8+ T cell responses against Ag85A/b
are robust in these studies, somewhat paralleling our ﬁndings, at
least qualitatively [4,5], of modest CD4+ and CD8+ T cell responses
against Ag85A/b, including both QFT-G(−) and, for the ﬁrst time,
QFT-G(+) subjects. The individual and grouped responses we  saw,
like others, were somewhat sporadic, and due to the small num-
ber of subjects, we  could not conclude that there were any notable
differences between the QFT-G(−) and QFT-G(+) subjects. Nonethe-
less, trends in the CD4+ T cell responses suggested boosting after the
second vaccine dose, slightly more so in QFT-G(+) subjects. Possible
reasons for the greater CD4+ and CD8+ responses against Ag85A/b
versus Mtb antigen TB10.4, also observed by and discussed by Hoft
et al., include immuno-dominance of Ag85 proteins, differential
protein expression by cells infected with AERAS-402, relative sta-
bility of the expressed antigens, and the 3 times larger size of Ag85A
and Ag85B versus Mtb antigen TB10.4, increasing the chances of
more T cell epitopes capable of stimulating immune responses in
humans of diverse HLA backgrounds [5]. In spite of poor cell quality,
our data at least seemed to re-conﬁrm the ability of AERAS-402 to
boost CD4+ and CD8+ T cell responses to BCG as seen by responses
to Ag85A/b, perhaps one part of an effective response to prevent TB
infection [5].
Past studies using Ad5 as a vaccine vector determined that
pre-existing neutralizing antibodies to Ad5 may  affect vaccine
immunogenicity, leading to different vector approaches such as
Ad35 [4]. Pre-existing neutralizing Ad35 antibodies in sub-Saharan
Africans is estimated to be about 20% (detectable, ≥16), simi-
lar to what we  found at screening; in contrast, seroprevalence
of Ad5 neutralizing antibodies is as high as 90% [11]. Here, in
comparison with Day 0, mostly minimal increases of Ad35 neu-
tralizing antibodies at Day 182 were seen in 8 (50%) subjects
after 2 doses of AERAS-402, consistent with ﬁndings from stud-
ies of 2 doses of AERAS-402 in 13 HIV-uninfected volunteers in the
United States [5] and 13 HIV-infected volunteers in South Africa
[6]. However, in a study in which HIV-uninfected South African
volunteers received 2 doses of AERAS-402, Ad35 neutralizing anti-
bodies were induced in 5 of 6 volunteers [4]. Results from these
small studies, along with our study, suggest that the Ad35 viral
vector is not especially immunogenic in regard to triggering forma-
tion of Ad35 neutralizing antibody, boding well for vaccines such as
AERAS-402.
Both AERAS-402 groups showed increases in mean PPD skin
test site induration at Day 182 versus screening, with a statisti-
cally signiﬁcant increase only in the AERAS-402 QFT-G(+) group.
Whereas this ﬁnding may  be considered interesting, or even sug-
gest some degree of BCG boosting by AERAS-402, it is known
PPD reactivity, even though it involves CD4+ T cells, does not
correlate with protection against TB. Given the small number of
subjects and poor repeatability of PPD tests, changes in PPD reac-
tivity could have been random, perhaps induced by exposure to
non-TB mycobacteria. Another possibility is that PPD reactivity
changes were due to the natural response of latent TB infec-
tion in the QFT-G(+) subjects, especially as there is no timeline
as to when TB infection occurred in these subjects. This is fur-
ther supported in the stratum with no latent infection [QFT-G(−)],
whereby PPD size did not change appreciably despite AERAS-402
vaccination.
In conclusion, in this small Phase 1 study, AERAS 402 appeared
similar in safety and tolerability as in other studies of BCG
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Fig. 3. (A–D) Antigen-speciﬁc T cell responses to AERAS-402. Speciﬁc CD4 and CD8 T cells were deﬁned by expression of any cytokine following incubation of PBMCs with
Ag85A/b (A and C), respectively, or TB10.4 (B and D), respectively in an ICS assay. Frequencies of cytokine-expressing cells in the DMSO control were subtracted to calculate
the  results shown (negative DMSO-subtracted results were set to zero). Results are shown as medians with interquartile ranges for placebo, and QFT-G(−) and QFT-G(+)
s  or pla
v
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t
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pubjects who  received AERAS-402. Arrows below Day 0 and 56 indicate AERAS-402
accinated adults, now to include for the ﬁrst time QFT(+) subjects.
mmunogenicity, although partly compromised by poor quality of
ome cell samples, was comparable to that seen in other studies
f AERAS-402 with no obvious differences between QFT(−) and
FT(+) subjects.
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